CRISPR Market Is Likely to Experience a Tremendous Growth during 2019-2025 | Analysis by Thermo Fisher, Editas Medicine, GenScript

A market study ”Global CRISPR Market” examines the performance of the Global CRISPR Market 2019. It encloses an in-depth Research of the CRISPR Market state and the competitive landscape globally. This report analyzes the potential of CRISPR Market in the present and the future prospects from various angles in detail.

Global CRISPR Market Overview:

The Global CRISPR Market to reach USD 6000 Million by 2025. The Global CRISPR Market is valued approximately USD 248 Million in 2015.

The growth is primarily driven by the rising demand for drug discovery and a significant rise in research spending. Further, increasing prevalence of genetic disorders due to late pregnancies and changing lifestyle patterns have drawn the significant attention of the researchers towards this emerging technology.

Available Exclusive Sample Copy of this Report @ .

On the basis of End-User, Biotechnology firms and Research & Development Institutes currently captures more than 60% of total revenue share. High investments from these end-user segments are the primary driving force for the adoption this emerging technology. However, during over forecast period, Pharmaceutical firms are expected to witness highest growth rate. Significant developments in the field of pharmaceutical biotechnology are expected to generate huge opportunities in coming years.

The global market is dominated by North America region followed by Asia Pacific. The rising prevalence of infertility and genetic disorders in the Asia Pacific region are the primary driving factors. Agriculture and Animal breeding are the emerging applications in the Asian countries. North America captures approximately 38% of the total revenue share in 2015. Europe is also an emerging region for the development of this technology.

Latest Business Updates:

Thermo Fisher Scientific (September 09, 2019) – Thermo Fisher Scientific Signs Agreement with Lilly Oncology for Companion Diagnostic to be Used with RET Inhibitor – Thermo Fisher Scientific today announced an agreement with Eli Lilly and Company for development of a companion diagnostic that will use the U.S Food and Drug Administration-approved, next-generation sequencing-based Oncomine Dx Target Test to identify certain non-small cell lung cancer (NSCLC) and thyroid cancer patients who may be treated with Lilly’s investigational therapy, LOXO-292. Specifically, the test would be used with patients whose tumors harbor a rearranged during transfection (RET) alteration. RET variants are found in about two percent of NSCLC, about 60 percent of medullary thyroid cancer (MTC) and up to approximately 20 percent of other thyroid cancers.

LOXO-292 is a highly selective and potent oral RET inhibitor being studied by Lilly in a Phase 1/2 clinical trial for the treatment of advanced cancers that harbor activating alterations of the RET kinase. Changes in the RET kinase, including fusions and mutations, can cause uncontrolled cell growth leading to tumor development. Cancers driven by such alterations are mostly dependent on this singularly activated pathway, making them highly susceptible to small molecule inhibitors.

“One of the biggest barriers to realizing the full power of precision medicine in oncology is having access to high-quality testing, such as next-generation sequencing-based tests, that identify a broad range of clinically actionable alterations, can be performed locally and allow treating institutions to participate in this important step in the evolving treatment paradigm,” said Anne White, president of Lilly Oncology. “With this agreement, we believe that more patients will gain access to high-quality tumor profiling, identifying those with RET alterations potentially suitable for LOXO-292 therapy, in addition to other alterations suitable for treatment with other therapies.

Purchase this report online with 120 Pages, List of Tables & Figures and in-depth Table of Contents on “Global CRISPR Market 2017-2025” @ .

Top Leading Key in Players Global CRISPR Market: Thermo Fisher Scientific, Editas Medicine, Caribou Biosciences, Intellia Therapeutics, Cellectis, Horizon Discovery, Sigma-Aldrich Corporation and others. New product launches and continuous technological innovations are the key strategies adopted by the major players.

With the presence of a large pool of participants, the Global CRISPR Market is displaying a highly competitive business landscape, finds a new research report by Business Industry Reports (BIR). Thermo Fisher Scientific, Editas Medicine, Caribou Biosciences, Intellia Therapeutics, Cellectis, Horizon Discovery, Sigma-Aldrich Corporation are some of the key vendors of CRISPR across the world. These players across CRISPR Market are focusing aggressively on innovation, as well as on including advanced technologies in their existing products.

Region segment: CRISPR Market report is segmented into several key regions, with sales, revenue, market share (%) and growth Rate (%) of CRISPR in these regions, from 2013 to 2025 (forecast), covering: North America, Europe, Asia Pacific, Middle East & Africa and South America

In the end, this report covers data and information on capacity and production overview, production, market share analysis, sales overview, supply, sales, and shortage, import, export and consumption as well as cost, price, revenue and gross margin of CRISPR Market.

Grab Your Report at an Impressive Discount @ .

Major Points in Table of Contents:

Global CRISPR Market Report 2018

1 Research Methodology

2 Global CRISPR Market Definition & Scope

3 Executive Summary

4 Global CRISPR Industry Dynamics

5 Global CRISPR Market by Application

6 Global CRISPR Market by End User

7 Global CRISPR Market, Regional Analysis

8 Competitive Intelligence

About us is digital database of comprehensive market reports for global industries. As a market research company, we take pride in equipping our clients with insights and data that holds the power to truly make a difference to their business. Our mission is singular and well-defined – we want to help our clients envisage their business environment so that they are able to make informed, strategic and therefore successful decisions for themselves.

Media Contact

Business Industry Reports

Pune – India



Leave a Reply

%d bloggers like this: